We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

44 hedge funds and large institutions have $12M invested in Spyre Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.25% less ownership

Funds ownership: 2.77% → 2.53% (-0.25%)

12% less funds holding

Funds holding: 50 → 44 (-6)

38% less capital invested

Capital invested by funds: $19.2M → $12M (-$7.21M)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
44
Holders Change
-6
Holders Change %
-12%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
9
Reduced
8
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$265K
2
CG
Carlyle Group
District of Columbia
+$106K
3
SFM
Sphera Funds Management
Israel
+$90.2K
4
Jane Street
Jane Street
New York
+$18.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$13.2K

Top Sellers

Rank Fund Capital Flow
1
PVI
Pura Vida Investments
New York
-$472K
2
GTC
Ghost Tree Capital
New York
-$360K
3
Two Sigma Investments
Two Sigma Investments
New York
-$32.1K
4
Morgan Stanley
Morgan Stanley
New York
-$29.3K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$27.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$1.55M – – –
NCM
2
Nantahala Capital Management
Connecticut
$1.32M -$23.4K -2,132 -1%
SCM
3
Suvretta Capital Management
New York
$1.18M – – –
Millennium Management
4
Millennium Management
New York
$1.08M +$265K +24,200 +19%
RSCM
5
Rock Springs Capital Management
Maryland
$990K – – –
BBA
6
Baker Bros. Advisors
New York
$989K – – –
SCM
7
Sio Capital Management
New York
$871K – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$579K – – –
O
9
OrbiMed
New York
$521K – – –
ACM
10
Aisling Capital Management
New York
$490K – – –
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$435K – – –
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$402K – – –
SB
13
Samsara BioCapital
California
$256K – – –
BlackRock
14
BlackRock
New York
$188K +$1.19K +108 +0.4%
SFM
15
Sphera Funds Management
Israel
$187K +$90.2K +8,226 +47%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$174K – – –
Two Sigma Investments
17
Two Sigma Investments
New York
$92.9K -$32.1K -2,926 -19%
Assenagon Asset Management
18
Assenagon Asset Management
Luxembourg
$92.4K – – –
UOTTAIMCU
19
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$71K – – –
CG
20
Carlyle Group
District of Columbia
$69K +$106K +9,620 New
State Street
21
State Street
Massachusetts
$62.3K – – –
Two Sigma Advisers
22
Two Sigma Advisers
New York
$61.1K -$27.2K -2,480 -23%
Renaissance Technologies
23
Renaissance Technologies
New York
$53K +$13.2K +1,200 +20%
BCM
24
Bridgeway Capital Management
Texas
$43.5K – – –
ECM
25
ExodusPoint Capital Management
New York
$34K +$5.37K +489 +12%
1
2 3

SYRE Hedge Fund Activity: Q1 2023 in Review

44 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2023, worth a combined $12M — down 38% from $19.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SYRE and 3 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 9 added.

The largest buyer was Millennium Management, adding an estimated $265K. The largest seller was Pura Vida Investments, exiting entirely with an estimated $472K sold.

  • 44 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2023, down from 50 in Q4 2022.
  • Funds reported $12M of Spyre Therapeutics stock for Q1 2023, down 38% quarter-over-quarter.
  • 3 funds opened new Spyre Therapeutics positions in Q1 2023 and 8 closed out, a net change of -5 holders.
  • The largest Spyre Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $265K added.
  • The largest Spyre Therapeutics seller in Q1 2023 was Pura Vida Investments, an estimated $472K sold.

Based on aggregated 13F filings for Q1 2023.